Disease Domain | Count |
---|---|
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Top 5 Target | Count |
---|---|
ALOX12 x Aldehydes x COX x Peroxidases | 1 |
Mechanism ALOX12 inhibitors [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Mechanism Hepatitis C virus NS 5 protein inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Sodium channels blockers |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date15 Nov 2024 |
Sponsor / Collaborator |
Start Date15 Jan 2024 |
Sponsor / Collaborator |
Start Date13 Nov 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Isoliquiritigenin ( ALOX12 x Aldehydes x COX x Peroxidases ) | Prostatic Cancer More | Preclinical |
KK-6168 ( Hepatitis C virus NS 5 protein ) | Hepatitis C More | Discontinued |
FY-504 ( Nav1.8 ) | Peripheral Nervous System Diseases More | Pending |
YD-307 ( Sodium channels ) | Neuralgia More | Pending |